NovoCure Limited (NVCR)
NVCR Stock Price Chart
Explore NovoCure Limited interactive price chart. Choose custom timeframes to analyze NVCR price movements and trends.
NVCR Company Profile
Discover essential business fundamentals and corporate details for NovoCure Limited (NVCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
1 Oct 2015
Employees
1.49K
Website
https://www.novocure.comCEO
Ashley Cordova
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Financial Timeline
Browse a chronological timeline of NovoCure Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.42.
Earnings released on 24 Jul 2025
EPS came in at -$0.36 surpassing the estimated -$0.39 by +7.69%, while revenue for the quarter reached $158.81M , missing expectations by 0.00%.
Earnings released on 24 Apr 2025
EPS came in at -$0.31 surpassing the estimated -$0.47 by +34.04%, while revenue for the quarter reached $154.99M , beating expectations by +0.73%.
Earnings released on 27 Feb 2025
EPS came in at -$0.61 falling short of the estimated -$0.34 by -79.41%, while revenue for the quarter reached $161.27M , beating expectations by +9.28%.
Earnings released on 30 Oct 2024
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $155.10M , beating expectations by +1.34%.
Earnings released on 25 Jul 2024
EPS came in at -$0.31 surpassing the estimated -$0.40 by +22.50%, while revenue for the quarter reached $150.36M , beating expectations by +4.52%.
Earnings released on 2 May 2024
EPS came in at -$0.36 surpassing the estimated -$0.43 by +16.28%, while revenue for the quarter reached $138.50M , beating expectations by +1.98%.
Earnings released on 22 Feb 2024
EPS came in at -$0.45 surpassing the estimated -$0.53 by +15.09%, while revenue for the quarter reached $133.78M , beating expectations by +1.54%.
Earnings released on 26 Oct 2023
EPS came in at -$0.46 surpassing the estimated -$0.52 by +11.54%, while revenue for the quarter reached $127.32M , missing expectations by -1.53%.
Earnings released on 27 Jul 2023
EPS came in at -$0.54 falling short of the estimated -$0.50 by -8.00%, while revenue for the quarter reached $126.05M , beating expectations by +1.44%.
Earnings released on 4 May 2023
EPS came in at -$0.50 falling short of the estimated -$0.36 by -38.89%, while revenue for the quarter reached $122.18M , missing expectations by -4.01%.
Earnings released on 23 Feb 2023
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%, while revenue for the quarter reached $128.43M , beating expectations by +0.90%.
Earnings released on 27 Oct 2022
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%, while revenue for the quarter reached $131.00M , beating expectations by +0.30%.
Earnings released on 28 Jul 2022
EPS came in at -$0.23 falling short of the estimated -$0.14 by -64.29%, while revenue for the quarter reached $140.87M , beating expectations by +4.37%.
Earnings released on 28 Apr 2022
EPS came in at -$0.04 surpassing the estimated -$0.17 by +76.47%, while revenue for the quarter reached $137.55M , beating expectations by +2.59%.
Earnings released on 24 Feb 2022
EPS came in at -$0.25 falling short of the estimated -$0.10 by -150.00%, while revenue for the quarter reached $133.21M , beating expectations by +0.16%.
Earnings released on 28 Oct 2021
EPS came in at -$0.13 falling short of the estimated -$0.06 by -116.67%, while revenue for the quarter reached $133.61M , beating expectations by +25.70%.
Earnings released on 29 Jul 2021
EPS came in at -$0.14 falling short of the estimated -$0.01 by -1.67K%, while revenue for the quarter reached $133.52M , missing expectations by -5.90%.
Earnings released on 29 Apr 2021
EPS came in at -$0.04 falling short of the estimated -$0.01 by -300.00%, while revenue for the quarter reached $134.70M , missing expectations by -3.63%.
Earnings released on 25 Feb 2021
EPS came in at $0.04 falling short of the estimated $0.12 by -66.67%, while revenue for the quarter reached $143.95M .
Earnings released on 29 Oct 2020
EPS came in at $0.09 surpassing the estimated $0.03 by +170.03%, while revenue for the quarter reached $132.66M , beating expectations by +200.00%.
NVCR Stock Performance
Access detailed NVCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.